The American College of Cardiology (ACC) 2021 scientific sessions took place virtually this year from 15-17 May. Here is our curated list of the top 10 highlights of these sessions. TALOS-AMI trial1: This trial followed 2697 patients who had experienced myocardial infarction (MI), undergone percutaneous coronary intervention (PCI), and completed 1 month of dual … [Read more...] about Top 10 Highlights of ACC 2021
Cardiology research news
The physical activity paradox in cardiovascular disease
Physical activity during leisure time is associated with a reduced risk of major adverse cardiovascular events (MACE) and all-cause mortality. In contrast, some research has suggested an increased risk of all-cause mortality in those with high levels of occupational physical activity. Prof. Andreas Holtermann (National Research Centre for the Working Environment, … [Read more...] about The physical activity paradox in cardiovascular disease
Effect of Empagliflozin on exercise ability and symptoms in heart failure patients
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms in patients with chronic heArt faiLure) trials evaluated the effect of 10 mg empagliflozin versus placebo on exercise ability in patients with heart failure. EMPERIAL-Reduced (NCT03448419) randomized 312 patients with heart failure with reduced ejection fraction (LVEF ≤ 40%) to receive either … [Read more...] about Effect of Empagliflozin on exercise ability and symptoms in heart failure patients
Renin-angiotensin system inhibitors improve transcatheter aortic valve replacement prognosis
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace narrowed aortic valves that fail to properly open. Following this procedure, however, left ventricular (LV) hypertrophy and myocardial fibrosis persist and are linked to worse prognosis. Renin-angiotensin system (RAS) inhibition can protect against these risks and in response to … [Read more...] about Renin-angiotensin system inhibitors improve transcatheter aortic valve replacement prognosis
Superior Cardiac Outcomes with addition of SGLT2i to GLP-1RA
Atherosclerotic cardiovascular disease and heart failure occur more frequently in patients with type 2 diabetes mellitus. Therefore, the major goal of care of patients with type 2 diabetes is to reduce the incidence of these events. Both glucagon-like peptide agonists (GLP-1RA’s) and sodium-glucose co-transporter 2 inhibitors (SGLT2i’s) can independently improve glucose control … [Read more...] about Superior Cardiac Outcomes with addition of SGLT2i to GLP-1RA